AGE and RAGE inhibitors in the treatment of diabetic retinopathy

Ashay Bhatwadekar, Alan W. Stitt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Diabetic retinopathy is a major complication of diabetes and several biochemical/molecular mechanisms have been proposed as key instigators in the initiation and progression of the condition. Accumulating evidence suggests that formation of advanced glycation end products (AGEs) within the diabetic milieu is one of the contributing factors to neural and microvascular abnormalities as retinopathy progresses. This review highlights the pathogenesis of diabetic retinopathy, with special emphasis on AGEs, their receptors and the potential role of AGE-inhibiting agents. Retinopathy may be associated with an upregulation of the receptor for AGEs (RAGE) in a proinflammatory axis, concomitant with increases in AGEs. Therefore, this review will also detail the role of RAGE in AGE trafficking, its various ligands and the possibilities for targeting RAGE for therapeutic exploitation to prevent retinopathy in patients with diabetes.

Original languageEnglish (US)
Pages (from-to)105-120
Number of pages16
JournalExpert Review of Ophthalmology
Volume2
Issue number1
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Medical problems
Ligands
Advanced Glycosylation End Products
Diabetes Complications
Therapeutics
Up-Regulation
Advanced Glycosylation End Product-Specific Receptor

Keywords

  • advanced glycation end products
  • diabetic retinopathy
  • receptor for advanced glycation end products

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Cite this

AGE and RAGE inhibitors in the treatment of diabetic retinopathy. / Bhatwadekar, Ashay; Stitt, Alan W.

In: Expert Review of Ophthalmology, Vol. 2, No. 1, 01.02.2007, p. 105-120.

Research output: Contribution to journalArticle

@article{78bee4dc1b994ae49346e78e6571d6d9,
title = "AGE and RAGE inhibitors in the treatment of diabetic retinopathy",
abstract = "Diabetic retinopathy is a major complication of diabetes and several biochemical/molecular mechanisms have been proposed as key instigators in the initiation and progression of the condition. Accumulating evidence suggests that formation of advanced glycation end products (AGEs) within the diabetic milieu is one of the contributing factors to neural and microvascular abnormalities as retinopathy progresses. This review highlights the pathogenesis of diabetic retinopathy, with special emphasis on AGEs, their receptors and the potential role of AGE-inhibiting agents. Retinopathy may be associated with an upregulation of the receptor for AGEs (RAGE) in a proinflammatory axis, concomitant with increases in AGEs. Therefore, this review will also detail the role of RAGE in AGE trafficking, its various ligands and the possibilities for targeting RAGE for therapeutic exploitation to prevent retinopathy in patients with diabetes.",
keywords = "advanced glycation end products, diabetic retinopathy, receptor for advanced glycation end products",
author = "Ashay Bhatwadekar and Stitt, {Alan W.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1586/17469899.2.1.105",
language = "English (US)",
volume = "2",
pages = "105--120",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - AGE and RAGE inhibitors in the treatment of diabetic retinopathy

AU - Bhatwadekar, Ashay

AU - Stitt, Alan W.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Diabetic retinopathy is a major complication of diabetes and several biochemical/molecular mechanisms have been proposed as key instigators in the initiation and progression of the condition. Accumulating evidence suggests that formation of advanced glycation end products (AGEs) within the diabetic milieu is one of the contributing factors to neural and microvascular abnormalities as retinopathy progresses. This review highlights the pathogenesis of diabetic retinopathy, with special emphasis on AGEs, their receptors and the potential role of AGE-inhibiting agents. Retinopathy may be associated with an upregulation of the receptor for AGEs (RAGE) in a proinflammatory axis, concomitant with increases in AGEs. Therefore, this review will also detail the role of RAGE in AGE trafficking, its various ligands and the possibilities for targeting RAGE for therapeutic exploitation to prevent retinopathy in patients with diabetes.

AB - Diabetic retinopathy is a major complication of diabetes and several biochemical/molecular mechanisms have been proposed as key instigators in the initiation and progression of the condition. Accumulating evidence suggests that formation of advanced glycation end products (AGEs) within the diabetic milieu is one of the contributing factors to neural and microvascular abnormalities as retinopathy progresses. This review highlights the pathogenesis of diabetic retinopathy, with special emphasis on AGEs, their receptors and the potential role of AGE-inhibiting agents. Retinopathy may be associated with an upregulation of the receptor for AGEs (RAGE) in a proinflammatory axis, concomitant with increases in AGEs. Therefore, this review will also detail the role of RAGE in AGE trafficking, its various ligands and the possibilities for targeting RAGE for therapeutic exploitation to prevent retinopathy in patients with diabetes.

KW - advanced glycation end products

KW - diabetic retinopathy

KW - receptor for advanced glycation end products

UR - http://www.scopus.com/inward/record.url?scp=41849096928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849096928&partnerID=8YFLogxK

U2 - 10.1586/17469899.2.1.105

DO - 10.1586/17469899.2.1.105

M3 - Article

VL - 2

SP - 105

EP - 120

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 1

ER -